Phibro Animal Health Q4 Earnings Call Highlights
Phibro Animal Health (PAHC) reported Q4 and full-year 2026 results, with legacy MFA and other revenue up 4%, Nutritional Specialties up 9%, and vaccine revenue up 14%. The company expects fiscal 2027 sales of $1.55B-$1.60B and adjusted EBITDA of $258M-$268M, with growth driven by acquired MFA products and international demand. However, Brazil regulatory uncertainty and higher input costs may impact performance. Phibro also plans to close its Chicago Heights facility, expecting $15M-$20M in annua
How this was made
The 30-second read
Why it matters
The earnings release introduces new revenue and EBITDA guidance, highlights Brazil regulatory risk, and outlines cost impacts from a plant closure.
Market read
First report of Q4 numbers and FY2027 outlook provides actionable data for traders and analysts covering animal health stocks.
What to watch
Capital expenditures for new vaccine capacity in Ireland/Israel and the Chicago Heights closure could improve margins over time.
Background
Phibro Animal Health (NASDAQ:PAHC) reported Q4 results, detailed segment performance, and provided FY2027 guidance.
Ticker impact
Q4 earnings release with revenue $1.55‑$1.60B guidance and updated EBITDA, dividend and Brazil regulatory outlook.
Potential modest upside if guidance beats consensus; downside risk if Brazil issues delay approvals.
First disclosure of full‑year numbers and forward guidance provides fresh data for valuation models.
Market effects
Animal health and mineral nutrition sector may see similar guidance trends; Brazil regulatory risk could affect peers.
North America and Latin America exposure highlighted; Brazil uncertainty may influence regional biotech stocks.
Guidance contributes to broader agribusiness outlook but limited global macro impact.
Counterpoint
Investors may short if they believe Brazil regulatory delays will materially hit revenue.
Key entities
- CompanyPhibro Animal Health Corporation
Subject of the earnings call and guidance.
- Regulatory BodyBrazil regulators
Uncertainty around therapeutic‑use approvals for virginiamycin.
